Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists
- 1 December 2015
- journal article
- review article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 418, 42-54
Abstract
No abstract availableKeywords
Funding Information
- Deutsches Zentrum für Diabetesforschung (DZD)
- Alexander von Humboldt Foundation
- Helmholtz Association
This publication has 115 references indexed in Scilit:
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in HumansCell Metabolism, 2011
- The metabolic actions of glucagon revisitedNature Reviews Endocrinology, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityGut, 2009
- Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat DietJournal of Biological Chemistry, 2008
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiesProceedings of the National Academy of Sciences, 2008
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Small-molecule agonists for the glucagon-like peptide 1 receptorProceedings of the National Academy of Sciences, 2007
- A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db miceProceedings of the National Academy of Sciences, 2007